X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/11/13/2779461/0/en/Hepion-Pharmaceuticals-Announces-Major-Reductions-in-Liver-Stiffness-with-Rencofilstat-Treatment-in-17-week-Phase-2-Study-of-Advanced-F3-MASH-Liver-Disease.html
https://www.globenewswire.com//news-release/2023/11/10/2778336/0/en/Hepion-Pharmaceuticals-Schedules-Conference-Call-to-Review-Additional-Efficacy-Data-from-Phase-2-ALTITUDE-NASH-Liver-Function-Trial-of-Rencofilstat.html
https://www.globenewswire.com//news-release/2023/10/25/2766519/0/en/Hepion-Pharmaceuticals-Rencofilstat-Demonstrates-Anti-Cancer-Activity-in-Hepatitis-C-Associated-Cancer-Model.html
https://www.globenewswire.com//news-release/2023/09/21/2747228/0/en/New-Anti-Cancer-Opportunities-Revealed-for-Hepion-Pharmaceuticals-Rencofilstat-in-Cancer-Screening-Program.html
https://www.globenewswire.com//news-release/2023/09/14/2743273/0/en/Rencofilstat-Produces-Positive-Outcomes-in-Translational-Study-on-Idiopathic-Pulmonary-Fibrosis.html
https://www.globenewswire.com/news-release/2023/05/19/2672786/0/en/Hepion-Pharmaceuticals-Schedules-Conference-Call-to-Review-Topline-Results-from-Phase-2-ALTITUDE-NASH-Liver-Function-Trial-of-Rencofilstat.html
https://www.globenewswire.com/news-release/2023/03/02/2619862/0/en/Hepion-Pharmaceuticals-to-Deliver-Updates-on-Ongoing-Phase-2-NASH-Clinical-Program-with-Rencofilstat-at-6th-Global-NASH-Congress.html
https://www.globenewswire.com/news-release/2023/03/02/2619444/0/en/EPO-Decision-to-Grant-European-Patent-for-Rencofilstat-Further-Strengthens-Hepion-s-Patent-Portfolio.html
https://www.globenewswire.com/news-release/2023/01/10/2586637/0/en/Presentation-of-Preclinical-Study-Highlighting-Anti-Cancer-Activity-of-Rencofilstat-in-Combination-with-Proteosome-Inhibitors.html
https://www.globenewswire.com//news-release/2023/01/05/2584130/0/en/Hepion-Pharmaceuticals-to-Present-Phase-2a-Rencofilstat-Multiomics-Data-at-NASH-TAG-2023.html
https://www.globenewswire.com/news-release/2022/06/20/2465336/0/en/Hepion-Pharmaceuticals-Receives-FDA-Orphan-Drug-Status-Designation-for-Rencofilstat-for-the-Treatment-of-Hepatocellular-Carcinoma.html
Market Place
Share 
